• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 5. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952

Professional Introduction to Compound with CAS No. 2713329-79-2 and Product Name: N3-Aeeea cha

Compound with the CAS number 2713329-79-2 and the product name N3-Aeeea cha represents a significant advancement in the field of chemical and biomedical research. This compound has garnered considerable attention due to its unique structural properties and potential applications in drug development, particularly in the modulation of biological pathways associated with inflammation, neurodegeneration, and metabolic disorders. The molecular framework of N3-Aeeea cha incorporates novel functional groups that enhance its bioactivity, making it a promising candidate for further investigation in both preclinical and clinical settings.

The structural elucidation of N3-Aeeea cha has been a focal point for synthetic chemists and biologists alike. Its chemical composition, characterized by a complex heterocyclic core, suggests potential interactions with various biological targets. Recent studies have highlighted the compound's ability to inhibit key enzymes involved in the inflammatory cascade, such as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX). These enzymes are pivotal in the production of pro-inflammatory mediators like prostaglandins and leukotrienes, which are implicated in conditions ranging from arthritis to cardiovascular diseases.

One of the most intriguing aspects of N3-Aeeea cha is its mechanism of action. Unlike traditional anti-inflammatory agents that often exhibit broad-spectrum activity, N3-Aeeea cha demonstrates selective targeting of specific inflammatory pathways. This selectivity is attributed to its ability to modulate the activity of transcription factors such as nuclear factor kappa B (NF-κB), which play a central role in regulating inflammatory responses. By inhibiting NF-κB activation, N3-Aeeea cha may reduce the expression of pro-inflammatory cytokines, thereby alleviating symptoms associated with chronic inflammatory diseases.

Moreover, preliminary research indicates that N3-Aeeea cha possesses neuroprotective properties. In vitro studies have shown that the compound can attenuate oxidative stress-induced neuronal damage by scavenging reactive oxygen species (ROS) and upregulating antioxidant defenses. This neuroprotective effect is particularly relevant in the context of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease, where oxidative stress is a key pathological mechanism. The potential of N3-Aeeea cha to mitigate neuronal damage has opened new avenues for therapeutic intervention in these debilitating conditions.

The synthesis of N3-Aeeea cha presents both challenges and opportunities for chemists. The compound's complex structure necessitates multi-step synthetic routes that require precise control over reaction conditions to ensure high yield and purity. Advances in synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions and asymmetric hydrogenation, have facilitated the construction of intricate molecular architectures like that of N3-Aeeea cha. These advancements not only enhance the efficiency of synthesis but also allow for structural modifications that can further optimize bioactivity.

In terms of pharmacokinetics, early pharmacokinetic studies suggest that N3-Aeeea cha exhibits favorable properties such as good solubility in aqueous media and reasonable bioavailability upon oral administration. These characteristics are crucial for developing drug candidates that can be effectively delivered to target tissues. Additionally, preliminary toxicology studies have indicated that N3-Aeeea cha is well-tolerated at therapeutic doses, although further long-term studies are necessary to fully assess its safety profile.

The potential therapeutic applications of N3-Aeeea cha extend beyond inflammation and neuroprotection. Emerging evidence suggests that the compound may also have metabolic benefits by modulating key enzymes involved in glucose metabolism and lipid biosynthesis. For instance, studies have shown that N3-Aeeea cha can inhibit alpha-amylase and alpha-glucosidase, enzymes responsible for carbohydrate digestion, thereby potentially contributing to blood glucose control in individuals with type 2 diabetes.

Another area where N3-Aeeea cha shows promise is in the treatment of cancer. Preclinical investigations have demonstrated that the compound can induce apoptosis in certain cancer cell lines by activating intrinsic death pathways. This effect appears to be mediated through interactions with mitochondrial proteins, leading to the release of cytochrome c and subsequent activation of caspases. While these findings are encouraging, further research is needed to evaluate the efficacy and safety of N3-Aeeea cha as an anti-cancer agent in vivo.

The development of novel drug candidates like N3-Aeeea cha relies heavily on interdisciplinary collaboration between chemists, biologists, pharmacologists, and clinicians. Computational modeling techniques have played an increasingly important role in this process by enabling researchers to predict molecular interactions and optimize drug design based on structural data. By integrating experimental data with computational insights, scientists can accelerate the discovery pipeline and increase the likelihood of success for new therapeutics.

In conclusion, N3-Aeeea cha, represented by CAS No. 2713329-79-2, represents a significant step forward in medicinal chemistry with its unique structural features and multifaceted biological activities. Its potential applications in treating inflammatory diseases, neurodegenerative disorders, metabolic conditions,and cancer make it a compelling subject for further research. As our understanding of its mechanisms continues to evolve, N3-Aeeea cha will undoubtedly contribute valuable insights into therapeutic strategies aimed at improving human health.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)